Acalabrutinib
Back to searchMolecule Structure
Scientific Name
Acalabrutinib
Description of the Drug
Acalabrutinib is a Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11703
http://www.drugbank.ca/drugs/DB11703
Brand Name(s)
Calquence
Company Owner(s)
Astrazeneca Uk Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tyrosine-protein kinase BTK | SINGLE PROTEIN | INHIBITOR | CHEMBL5251 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL14637368 | |
| DrugBank | DB11703 | |
| PubChem | 71226662 | |
| BindingDB | 50175583 | |
| DrugCentral | 5260 | |
| ChemicalBook | CB22756514 | |
| Guide to Pharmacology | 8912 | |
| rxnorm | ACALABRUTINIB | CALQUENCE |
| ChEBI | 167707 | |
| ZINC | ZINC000208774715 |
